S
Syndax Pharmaceuticals, Inc. (SNDX)
NMS – Real Time Price. Currency in USD
19.80
-0.49 (-2.41%)
At close: Aug 12, 2026, 4:00 PM EDT
20.08
+0.28 (1.41%)
After-hours: Aug 12, 2026, 5:40 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
19.80
-0.49 (-2.41%)
At close: Aug 12, 2026, 4:00 PM EDT
20.08
+0.28 (1.41%)
After-hours: Aug 12, 2026, 5:40 PM EDT
No Data
There are no news for this stock.
Total debt $589.4M significantly exceeds cash reserves ($336.5M), raising financial stability concerns
Total current assets $675.0M exceed Total current liabilities $99.7M, highlighting excellent liquidity
Debt-to-equity ratio (39.0) far exceeds the industry average, reflecting over-leverage
Interest coverage ratio (-3.2x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$30.3M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 6.77 | 6.05 | 10 | |
| Quick ratio | 6.44 | 5.63 | 10 | |
| Debt to Equity | 39.03 | 0.30 | 2.0 | |
| Debt to Assets | 0.84 | 1.04 | 2.0 | |
| Interest coverage | -3.16 | -16.91 | 1.0 | |
| Weighted average score | 5.0 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | 24M | 172M | 252M |
| Gross Profit | -454K | -12K | 23M | 165M | 242M |
| Operating Income | -152M | -230M | -340M | -273M | -194M |
| Net Income | -149M | -209M | -319M | -285M | -221M |
| EBITDA | -151M | -230M | -340M | -273M | -194M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 88.82 | 36.71 | 10 |
| Next quarter | 48.86 | 48.7 | 10 |
| Current year | 89.78 | 42.64 | 10 |
| Next year | 47 | 64.39 | 10 |
| Weighted average score | 10 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 12.22 | -15.67 | -14.57 | 39.79 | 4.8 |
| Y/Y | 91.76 | 31.29 | 33.73 | 65.47 | 10 |
| 3y average | 875.28 | -27.31 | -11.45 | -36.27 | 3.3 |
| 5y average | 2327.08 | -129.74 | -104.23 | -105.8 | 3.3 |
| Weighted average score | 5.4 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |